4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European Medical Information Framework (EMIF)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet
64
Participants partenaires
TERMINÉ
Recognising Adverse Drug Reactions (WEB-RADR)
Date du début: 1 sept. 2014, Date de fin: 31 août 2017,
WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Voir le projet
20
Participants partenaires
TERMINÉ
Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,
RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this bottleneck results from: a lack of useful and validated biomarkers, underperforming pre-clinical models, inadequate and incomplete sub-phenotyping, and insufficient disease understanding.HypothesisThe use of biomarker profiles comprised of various types of hi ...
Voir le projet
42
Participants partenaires
TERMINÉ
Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)
Date du début: 1 sept. 2009, Date de fin: 30 avr. 2015,
Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Voir le projet